Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables Refunds
Ratios

Silence Therapeutics (SLN) Receivables Refunds (2019 - 2025)

Silence Therapeutics' Receivables Refunds history spans 7 years, with the latest figure at $2.6 million for Q4 2025.

  • For Q4 2025, Receivables Refunds rose 69.29% year-over-year to $2.6 million; the TTM value through Dec 2025 reached $2.6 million, up 69.29%, while the annual FY2025 figure was $2.6 million, 69.29% up from the prior year.
  • Receivables Refunds for Q4 2025 was $2.6 million at Silence Therapeutics, up from $1.5 million in the prior quarter.
  • Across five years, Receivables Refunds topped out at $21.9 million in Q4 2023 and bottomed at $1.5 million in Q4 2024.
  • The 5-year median for Receivables Refunds is $9.4 million (2021), against an average of $10.6 million.
  • The largest annual shift saw Receivables Refunds skyrocketed 100.43% in 2021 before it tumbled 92.96% in 2024.
  • A 5-year view of Receivables Refunds shows it stood at $9.4 million in 2021, then skyrocketed by 86.32% to $17.5 million in 2022, then grew by 25.33% to $21.9 million in 2023, then crashed by 92.96% to $1.5 million in 2024, then soared by 69.29% to $2.6 million in 2025.
  • Per Business Quant, the three most recent readings for SLN's Receivables Refunds are $2.6 million (Q4 2025), $1.5 million (Q4 2024), and $21.9 million (Q4 2023).